ADC Therapeutics SA (ADCT) Stock: Buy, Sell, or Hold?
ADCT - ADC Therapeutics SA
$1.13
0.05 (4.63%)
▲
5d:
-11.02%
30d:
-14.39%
90d:
-9.6%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When ADCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ADCT is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ADCT is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ADCT is currently trading at $1.13, which is considered fair relative to its 30-day fair value range of $1.06 to $1.27.
Technical Outlook: Technically, ADCT is in a strong downtrend. Immediate support is located at $1.03, while resistance sits at $1.32. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.33 (+195.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADCT is in a strong downtrend. Immediate support is located at $1.03, while resistance sits at $1.32. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.33 (+195.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.06 -
$1.27
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 195.0% below Wall St target ($3.33)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.06 -
$1.27
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.32
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.67
Wall Street Target
$3.33
(+195.0%)
Revenue Growth (YoY)
2.2%
Profit Margin
-121.8%
Share & Embed Analysis
Last updated: October 03, 2026 2:59 AM ET
Data refreshes hourly during market hours. Next update: 3:59 AM
Data refreshes hourly during market hours. Next update: 3:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
